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An In Vitro And In Vivo Evaluation of The Anticancer Potential Of Resveratrol And 
Pterostilbene Against Hpv-E6 Positive Cancers. 
By 
Kaushiki Chatterjee 
Advisor: Dr. Jimmie E. Fata 
 
Cervical cancer remains as one of the most prevalent cancers effecting women globally. Lack of 
awareness and affordable prophylactic and therapeutic options in developing countries drive the 
need for alternative low-cost approaches. Dietary polyphenols have gained increased attention as 
possible anti-cancer agents. Our study aims to investigate whether two natural structural analogs, 
resveratrol and pterostilbene, exhibit anti-HPV (Human papillomavirus) activity in cervical 
cancer. To determine the efficacy of these polyphenols, extensive in vitro and in vivo analyses 
were carried out. For the in vitro studies we utilized human HeLa cells (HPV18 positive) and 
murine TC1 cells (HPV 16 oncogene positive). Both these plant polyphenols show efficacy 
against these cell lines with low IC50 values in the µM range.  In HeLa cells we looked at E6 
protein expression, downstream p53 expression and activation of caspase 3 as a means to 
understand the mechanism of action. Both resveratrol and pterostilbene showed efficacy against 
HeLa by eliciting S-phase growth arrest, decreasing mitotic activity and impairing it’s 
clonogenicity. These findings were significant, with pterostilbene often being more effective 
than resveratrol. Results point to a possible mechanism in HPV18 which involves the 
downregulation of HPV E6 oncogene, stabilization of functional p53 and activation of the 
apoptotic pathway. Further in vitro analysis on TC1 cells confirmed the cytotoxic potential of 
both resveratrol and pterostilbene and their ability to downregulate E6 oncoprotein. Our in vivo 
studies on TC1 tumors established in mice elucidated that both compounds substantially decrease 
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tumor load with E6 and VEGF protein downregulation. Intriguingly, the tumor reduction induced 
by pterostilbene is caused by apoptosis via activation of caspase 3, whereas, the efficacy of 
resveratrol is a due to growth arrest indicated by suppressed PCNA expression. Thus, our results 
show the antineoplastic potential of resveratrol and pterostilbene against both HPV18 and 
HPV16 cervical cancers. These findings show their robust anti-tumor potential and warrants the 
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1.1 Cervical cancer; Need for an alternative therapy 
Cervical cancer is one of the most prevalent cancers affecting women worldwide. It is the second 
most common cancer in developing countries and 11th in developed countries. These regional 
differences are often attributed to the lack of Pap smears, a preventative procedure often absent 
in underdeveloped areas [1,2]. It is widely accepted that the etiological factor that causes cervical 
cancer is chronic infection of the human papilloma virus (HPV), which is considered the most 
common sexually transmitted infection [3]. Every year about 500,000 women acquire the disease 
and 75% are from the developing countries [4]. Moreover, recent evidence indicates that HPV 
infection is on the rise in men, leading to higher incidences of penile and oropharyngeal cancers 
[5]. HPVs can be clinically classified as “low-risk” (LR-HPV) or “high-risk” (HR-HPV) 
depending on the relative tendency of the HPV lesions to transform into malignancy. HPV 16 
and HPV 18 are the two most important cancer-causing, high-risk HPV [6]. HPV progression to 
cancer is dependent on prolonged infection by these high-risk HPV viruses. The progression of 
HPV lesions to a neoplastic stage is dependent on several co-factors. Currently there are a few 
standard treatment methods for cervical cancer including surgery, radiation and chemotherapy 
[7]. These treatment methods have several side effects including urinary dysfunction and sexual 
dysfunction [8,9]. Studies have also shown that these treatment therapies have a negative impact 
on the quality of life of survivors [10,11]. Although there are approved HPV vaccines and drugs 
available, a problem is the affordability of these drugs in low income areas [12]. Two such 
vaccines are Cervarix® and Gardasil® [13], which renders prophylactic actions against cervical 
lesions associated with the most common oncogenic HPV types, 16/18, but effective therapeutic 
measures for post-infection lesions are currently not available. The major concern for the 
common chemotherapeutic medicines like cisplatin and paclitaxel are their adverse side effects 
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[14,15]. Even after surviving cancer after chemotherapy there may be severe long term effects 
including ototoxicity, nephrotoxicity, neurotoxicity and even secondary malignancies [16]. 
Targeted therapies using antibodies are used to treat metastatic and recurrent cervical cancer [7]. 
The detrimental side effects of antiangiogenic targeted drugs such as Avastin steer the need for 
an alternative treatment[17].  
1.2 Natural compounds and cervical cancer 
Carcinogenesis is a multi-step process from initiation to progression. Natural products derived 
from plant sources have been known to have therapeutic potential since ancient times 
[18].Natural compounds have been known to have several anticancer properties and are able to 
target several key factors essential for cancerous progression [19]. Phytochemicals like 
polyphenols, carotenoids and alkaloids have shown anti-tumor potential in different types of 
cancers. Of the varied groups of natural products, polyphenols have gained increased importance 
in cervical cancer since they have displayed potent antitumor properties in a number of cancers 
by targeting several pathways that are involved in cancer progression [20,21]. Several studies 
have shown polyphenols to be highly bioactive in attenuating cervical cancer progression 
[19,22]. The most studied polyphenols in cervical cancer are curcumin found in turmeric 
rhizome and epicatechin gallate found in green tea. Other polyphenols that induce apoptosis and 
inhibit tumor progression are resveratrol, luteolin, quercetin, fisetin etc. [19]. Efforts have been 
made to find natural product combinations that have increased efficacy both in vitro and in vivo 
[21].  The development of natural chemoprotective drugs that effectively target HPV infection 
could drastically reduce the incidence and progression of cervical cancer worldwide if they are 




1.3 Resveratrol and Pterostilbene: A class of bioactive polyphenols 
The current study uses cervical cancer cells to compare the tumor-inhibitory effects and 
mechanism of action of two such polyphenols, resveratrol and pterostilbene. Both resveratrol and 
pterostilbene have been found by HPLC to be the major constituents of  ancient ayurvedic 
medicine 'Darakchasava' [23]. Both these compounds are stilbenes, which are a class of natural 
polyphenolic compounds that have been studied for their anticarcinogenic activities. 
 Resveratrol (3,4,5-trihydroxy-trans-stilbene), a natural polyphenol (Illustration1A), was first 
isolated and characterized in 1940 by Takaoka from the roots of Veratrum grandiflorum [24].  
Later it has been isolated from several plant species including grapes, red wine, purple grape 
juice, peanuts, berries, and some medicinal plants [25]. Resveratrol is a widely studied stilbene 
compound having very low toxicity in the human system, and it is also known to modulate 
several pathways that are directly linked to cancer progression [26]. Resveratrol is a debated 
compound amongst scientists and often termed as a pan assay interfering compound 
[27].However scientists continue to find various beneficial properties of resveratrol in cancer and 
other diseases [28,29].  Previous studies by our team have used resveratrol in combination with 
bioactive polyphenols curcumin and epicatechin gallate. There was evidence of superior efficacy 
and synergism in both cervical cancer and glioblastoma [30,31]. We wanted to explore the 
potential of resveratrol alone on cervical cancer and to understand the underlying mechanism of 
action.   Both in vitro and in vivo cancer studies have shown resveratrol to inhibit cell 
proliferation and angiogenesis along with inducing pro-apoptotic signals [32]. Resveratrol has 
been widely studied on cervical cancer and has shown promising results (Table 1). Multiple 
clinical trials using resveratrol have shown promising results (Table 2). In spite of several in 
vitro studies there is a dearth of in vivo or clinical studies of resveratrol on cervical cancer.  The 
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potential problem of using resveratrol as a chemoprotective agent is that it has low systemic 
bioavailability, which might lower its efficacy in the human system [33]. In order to overcome 
this, several efforts are being made to develop resveratrol derivatives with higher systemic 
bioavailability [34]. We set out to look for a better alternative to resveratrol. 
 
Illustration 1. Structure of resveratrol and pterostilbene 
Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene) is a naturally derived dimethylether 
analogue of resveratrol (Illustration 1B). Pterostilbene is believed to be produced in plants as a 
defense mechanism against some external microbial or fungal infection and is therefore 
considered a phytoalexin [35]. It has been isolated from grapevine leaves and blueberries [36]. 
Recently, pterostilbene has gained much attention as a possible anticancer agent, showing no 
toxicity in humans up to a dose of 250 mg/day [36,37]. Although the chemical structure of 
pterostilbene is closely related to resveratrol, the substitution of the hydroxyl group with a 
methoxy group in pterostilbene is believed to make the molecule more stable as well as increase 
its capacity to enter cells [38]. In addition, clinical studies have shown that the half-life and oral 
bioavailability of pterostilbene are significantly greater than those of resveratrol [37]. Studies on 
colon cancer cell lines have shown pterostilbene to be more potent than resveratrol in inhibiting 
DNA synthesis and in decreasing the expression of inflammatory genes responsible for cancer 
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progression [39]. Although studies in other types of carcinomas show the potential efficacy of 
resveratrol and pterostilbene, there has been barely any study to the best of our knowledge that 
explores an anticancer mechanism that is specific for HPV-positive carcinoma (Table 1). Few 
studies have utilized in vivo tumor models to determine the effectiveness of these two 
compounds including pancreatic, colon and liver cancer [26,28,40–43]. Although several studies 
delve into the pharmacokinetics and bioavailability of resveratrol and pterostilbene very little is 
known about their in vivo potential in HPV positive cancer. 
Table 1: Biological activity of resveratrol and pterostilbene on cervical cancer. 
Compound Study Type Mechanism of 
action 
Reference 
Resveratrol In vitro Apoptosis, Cell cycle 
arrest 
[44,45] 
In vitro Suppresses migration 
and invasion 
[46] 
In vitro Wnt, Notch, STAT3 
 
[47] 
In vitro HIF-1α/VEGF 
 
[48] 
In silico Interacts with p53 
binding site of E6 
[49] 
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1.4 Role of high risk E6 in pathogenesis of Cervical cancer 
Persistent infection with high risk HPV leads to cancer progression. The process involves 
integration of the viral DNA into the host genome resulting in uncontrolled cellular proliferation. 
As a result of this the virus loses its replicative property along with most of the viral 
genes[51,52]. 
 




Viral oncogenes E6 and E7 are required for cellular transformation and malignancy. E6 is a vital 
HPV oncoprotein essential for cervical cancer progression [53,54]. E6 binds to tumor suppressor 
protein p53 and targets it for degradation by the ubiquitin proteasome pathway [51], thus causing 
uncontrolled cell proliferation. Besides p53 E6 has several binding partners that target cellular 
signaling pathways responsible for metastasis (Illustration 3). Some of the major targets of E6 
















1.5 Scope of Work 
In the current project, we first set out to compare the relative effectiveness of resveratrol and 
pterostilbene on HeLa cells (HPV18), paying particular attention to their comparative IC50 
values, changes in the levels of the HPV oncoprotein E6 and its target p53, as well as their 
comparative pro-apoptotic and anti-migratory capacities (Chapter 2). 
Further in Chapter 3 we set out to examine the efficacy of both these compounds in vivo. For this 
purpose, we used a cervical cancer murine model injected with TC1 cells. These cells were 
originally derived from mouse primary lung epithelial cells transformed with three oncogenes: 
HPV16-E6, -E7 and c-Ha-Ras. TC1 tumor models have been widely used as a model for cervical 
cancer and have been used to study in vivo effects of several therapeutic strategies [21,55,56]. 
Unlike resveratrol there are very few studies on the effects of pterostilbene in cervical cancer. 
Furthermore, there is very little known about the anticancer effects of resveratrol and 
pterostilbene in vivo in cervical cancer. In this study we comprehensively analyzed the efficacy 
of these two polyphenols in HPV-oncogene positive tumors and explored the therapeutic 
possibility of these natural compounds in vitro and in vivo. Our findings show for the first time 
that these compounds can significantly reduce the size of HPV E6-oncogene positive TC1 
tumors. Importantly, both compounds significantly reduced HPV E6, the oncoprotein driving 
tumor formation. Only a short treatment cycle of 5 days was sufficient to see a significant 
antitumor potential of resveratrol and pterostilbene. We propose that this antitumor efficacy is 
dependent on two different mechanisms where resveratrol plays a vital role in arresting tumor 
growth evident by a significant reduction of proliferating cell nuclear antigen (PCNA) and 













Resveratrol and Pterostilbene Exhibit Anticancer Properties 
Involving the Downregulation of HPV Oncoprotein E6 in Cervical 
Cancer Cells 














Cervical cancer is one of the most common cancers in women living in developing countries. 
Due to a lack of affordable effective therapy, research into alternative anticancer compounds 
with low toxicity such as dietary polyphenols has continued. Our aim is to determine whether 
two structurally similar plant polyphenols, resveratrol and pterostilbene, exhibit anticancer and 
anti-HPV (Human papillomavirus) activity against cervical cancer cells. To determine anticancer 
activity, extensive in vitro analyses were performed. Anti-HPV activity, through measuring E6 
protein levels, subsequent downstream p53 effects, and caspase-3 activation, were studied to 
understand a possible mechanism of action. Both polyphenols are effective agents in targeting 
cervical cancer cells, having low IC50 values in the µM range. They decrease clonogenic 
survival, reduce cell migration, arrest cells at the S-phase, and reduce the number of mitotic 
cells. These findings were significant, with pterostilbene often being more effective than 
resveratrol. Resveratrol and to a greater extent pterostilbene downregulates the HPV oncoprotein 
E6, induces caspase-3 activation, and upregulates p53 protein levels. Results point to a 
mechanism that may involve the downregulation of the HPV E6 oncoprotein, activation of 
apoptotic pathways, and re-establishment of functional p53 protein, with pterostilbene showing 








2.2 Materials and Methods  
 
2.2.1 Cell Culture  
Human cervical carcinoma HeLa cells were obtained from a commercial supplier (American 
Type Culture Collection, Manassas, VA, USA) and were cultured in Dulbecco’s Modified Eagle 
Medium: Nutrient Mixture F-12 (DMEM/F-12) (HyClone, GE Healthcare Life Sciences, 
Manassas, VA, USA), supplemented with 10% fetal calf serum (HyClone, GE Healthcare Life 
Sciences) and 0.1% Penicillin-Streptomycin Solution (HyClone). Cells were incubated in a 37 
°C incubator with 5% CO2.  
2.2.2 Determination of IC50 Using WST-1 Assay 
Seven thousand cells were plated on 96-well plates and allowed to grow for 24 h. Resveratrol 
(Acros, #430075000) or pterostilbene (TCI, #P1924) was serially diluted from 10–120 µM into 
DMEM/F-12 plus 1× insulin-transferrin-selenium (ITS) supplement (Invitrogen). Cells were 
treated with dilutions (in triplicate) for 24 h prior to performing a WST-1 (Water Soluble 
Tetrazolium salt-1) cell viability assay. The WST assay involved aspiration of the medium after 
treatment and rinsing three times with equal volumes of 1×Phosphate Buffered Saline (PBS), 
followed by the addition of 80 µL of 10% WST-1 (Clontech, Mountain View, CA, USA) in 
DMEM to each well. The plate was then incubated at 37 °C for 1 h and absorbance monitored at 
440 nm using a plate reader. Results obtained were analyzed using GraphPad Prism 5 software to 




2.2.3 Live Imaging 
Images of untreated and treated (with resveratrol and pterostilbene) cells were taken every 10 
min for 24 h to generate video files using a Zeiss Axio Observer Z1 microscope. 
2.2.4 Clonogenic Assay 
Two hundred thousand cells were plated on 6-well plates and allowed to grow for 24 h prior to 
treatment with pterostilbene (50 µM) and resveratrol (50 µM) for 24 h. After 24 h, cells were 
trypsinized to single cell suspensions. After cell counting, 150 viable cells from each treatment 
set were plated in one well from a 6-well plate and allowed to grow in complete DMEM/F-12 
medium for 15 days. After said period of time, cells were washed once with 1× PBS then fixed 
and stained with 0.5% crystal violet in 6% glutaraldehyde for 30 min. The cells were briefly 
rinsed with tap water and allowed to air dry. Images of each well was taken and colonies were 
counted using ImageJ (NIH, Bethesda, Rockville, MD, USA). The plating efficiency and 
survival factor was calculated as determined previously [59] 
2.2.5 Scratch Assay  
Twelve thousand cells were grown on 96-well plates until a confluent monolayer was formed. A 
scratch was made with a sterile p200 tip in each well through the center of the culture. The debris 
was washed off with serum-free media and a marking was made on the bottom of the plate to 
take images at the same location. Cells were then treated with different concentrations (5 µM and 
20 µM) of resveratrol or pterostilbene and brightfield images were taken after 48 h to allow 
closure of the control scratch. The images were analyzed using ImageJ and the area of closure 




2.2.6 Flow Cytometry  
Two hundred and fifty thousand cells were cultured on 6-well plates and subsequently treated 
with resveratrol or pterostilbene (5 µM, 10 µM, and 15 µM) for 18 h. Cells were trypsinized, 
centrifuged, and washed with 0.1% Fetal Calf Serum (FCS) in 1× PBS solution and resuspended 
in 70% ethanol at −20 °C, which was added dropwise while shaking the samples vigorously. 
Fixed samples were kept at 4 °C for 1 h followed by washing twice in 1× PBS. Prior to flow 
cytometry, cells were incubated with RNase (500 µg/mL) for 30 min at 37 °C and then stained 
with propidium iodide (PI; 70 µM) for 30 mins. Cells were analyzed for DNA content by 
measuring PI fluorescence using an Accuri C6 flow cytometer (BD).  
2.2.7 Western Blot Analysis 
Two hundred and fifty thousand cells were cultured on 6-well plates and subsequently treated 
with resveratrol (10 µM, 50 µM) or pterostilbene (10 µM, 50 µM) for a period of 22 h. 
Extraction of proteins from cultured cells was performed using M-PER Mammalian protein 
extraction reagent (Thermo Fisher, Waltham, MA, USA) with protease and phosphatase 
inhibitors. The total amount of protein in each well was quantified using the Lowry method. To 
resolve the proteins, 25 μg of protein was subjected to sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis using a 10% acrylamide separating gel and then transferred to nitrocellulose 
membrane for 1 h. The membrane was blocked at room temperature for 1 h with 5% nonfat dry 
milk in Tris Tween Buffered Saline (TTBS). The nitrocellulose membrane was then incubated 
overnight with a p53 antibody (sc-6243) followed by incubation at room temperature for 1 h with 
anti-rabbit IgG conjugated with horseradish peroxidase. SuperSignal West Pico 
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chemiluminescence substrate (Pierce) was used for detection following the manufacturer’s 
instructions. The membranes were scanned using APHA INNOTECH Fluorchem SP imaging 
system. Analysis of blots was done using ImageJ software. 
2.2.8 Immunocytochemistry 
Seven thousand HeLa cells were plated on 8-well chamber slides and allowed to grow for 48 h. 
Cells were then treated with different concentrations of resveratrol (5–50 µM) or pterostilbene 
(5–50 µM) for 22 h (for study of E6, p53 and cleaved caspase-3) and 18 h (for study of Phospho 
histone H3). All treatments were performed in serum-free DMEM/F-12 containing 1% 
supplement (ITS; insulin, transferrin, selenium; Gibco BRL, Grand Island, NY, USA). After 
treatment, cells were fixed in 4% paraformaldehyde at room temperature, rinsed with 1× PBS, 
and then permeabilized and blocked with 10% horse serum, 2% bovine serum albumin, and 0.5% 
Triton X-100 in PBS for 1 h. The cells were then incubated overnight with primary antibodies in 
blocking buffer. Subsequent to primary antibody treatment, the cells were washed and then 
incubated with the respective Fluorescein isothiocyanate (FITC) conjugated secondary 
antibodies for 3 h, followed by incubation with 4’,6-diamidino-2-phenylindole (DAPI) (10 
µg/mL) and three washes with 1× PBS. The slides were then mounted with coverslips and cell 
images were acquired using a Zeiss Axio Observer Z1 microscope and an AxioVision 4.6.3-AP1. 
Images of different, randomly chosen fields were acquired with identical exposure times from 
each well for quantification. ImageJ was used to measure the fluorescence intensity and cell 
counting. The fluorescence intensities of E6 and P53 antibodies were normalized to DAPI 
intensity (blue).  
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Antibodies Used: E6 antibody (sc-460, Santa Cruz Biotechnology, Dallas, TX, USA), p53 
antibody (sc-6243), cleaved caspase-3 antibody (D175, 9661, CST), Phospho Histone H3 (Ser 
10) antibody (06–570, Millipore, Burlington, MA, USA). 
2.2.9 Statistical Analysis 
Statistical analyses were performed using Microsoft Excel® 2013 (Microsoft Corporation, 
Redmond, WA, USA) and GraphPad Prism® 5 (GraphPad Software, Inc., La Jolla, CA, USA). 
Means and standard deviations were calculated for each group. One-way ANOVA with Tukey 
test was used to compare three or more datasets and determine the significance between the 
groups. ANOVA is a test of variance and post hoc Tukey test used is for the determination of 
















2.3.1 Pterostilbene Is More Potent in Eliminating HPV+ HeLa Cells Compared to 
Resveratrol 
In order to study the comparative cytotoxicity of pterostilbene and resveratrol on HeLa tumor 
cells, brightfield images (Figure 1A) and WST-1 cell viability assays (Figure 1B) were 
performed 24 h post-treatment. The brightfield images taken after 24 h of treatment (Figure 1A) 
showed that pterostilbene (40 µM) eliminates significantly more cells than resveratrol at the 
same concentration. Live imaging of cells treated with 60 µM of the two compounds show 
significantly more death and characteristic apoptotic blebbing in pterostilbene-treated cells when 
compared to untreated or resveratrol-treated cells (Videos S1–S3). The WST-1 analysis revealed 
that although both pterostilbene and resveratrol eliminated HeLa cells significantly and in a 
dose-dependent manner, pterostilbene displayed a 1.97-fold lower IC50 when compared to 
resveratrol (42.3 µM vs. 83.5 µM; p < 0.05; Figure 1B). Additionally, both compounds, at 50 
µM, significantly inhibited the clonogenicity of post-treated cells in a 15-day clonogenic assay 
(Figure 1C). Pterostilbene significantly reduced clonogenic survival by 87.5% compared to the 
control (p < 0.05), while resveratrol inhibited it by 63% (p < 0.05) (Figure 1C). Moreover, the 




Figure 1. Pterostilbene is more potent in eliminating HeLa cervical cancer cells as 
compared to resveratrol: (A) Brightfield analysis of HeLa cells untreated (Ai) or treated for 24 
h with 40 µM of resveratrol (Res; Aii) or 40 µM of pterostilbene (Pte; Aiii). Evidence of cell 
elimination was only seen robustly in cells treated with pterostilbene at 40 µM. (B) Analysis of 
IC50 values, generated by a Water Soluble Tetrazolium salt-1 (WST-1) assay after 24 h of 
exposure to resveratrol or pterostilbene indicates that pterostilbene (IC50 = 42.3 µM) is a more 
potent cytotoxic agent than resveratrol (IC50 = 83.5 µM; Bii). The graphs represent data from 
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three independent experiments (mean ± S.E.M. (Standard error mean)). (C) Clonogenic assays 
performed to compare the relative effect of the two polyphenols on the clonogenicity of HeLa 
cells untreated (Ci) or treated with 50 µM of either resveratrol (Cii) or pterostilbene (Ciii). 
Results are from 15-days post-treatment and indicate that pterostilbene is more efficient in 
curbing the clonogenicity compared to resveratrol (Civ). Bar graph represents data from three 
independent experiments (mean ± S.E.M.; * p < 0.05; Civ). 
2.3.2 Inhibition of Cell Migration of HeLa Cells Treated with Pterostilbene and Resveratrol 
To determine the comparative efficacy of resveratrol and pterostilbene in inhibiting HeLa cell 
migration, two different sub-lethal concentrations of each compound were used in a 48-h scratch 
assay (Figure 2). Based on the WST-1 results and brightfield images (unpublished), we found 
that cells treated with a concentration below 25 µM showed no signs of cellular toxicity. To 
avoid any cytotoxicity, we used lower concentrations of 5 µM and 20 µM. At sub-lethal 
concentrations of 5 µM and 20 µM, both resveratrol and pterostilbene significantly inhibited 
HeLa cell migration relative to untreated cells (p < 0.05; Figure 2). Pterostilbene was more 
effective in inhibiting HeLa cell migration at 20 µM when compared to resveratrol; however, this 
result was not significant and no differences were seen between the two compounds at 5 µM 
(Figure 2). In an effort to analyze the effects of resveratrol and pterostilbene on cell migration, 
we normalized the amount of migration into the scratch (wound) by untreated cells, to 100%. 
Relative to this control, resveratrol-treated cells migrated only 71.2% (5 µM) and 63.7% (20 





Figure 2. Resveratrol and pterostilbene inhibit cell migration: (A) HeLa cells were 
monitored for cell migration into a scratched “wound”. Cells were either untreated or treated 
with sub-lethal concentrations (5 µM and 20 µM) of resveratrol (Res) or pterostilbene (Pte). The 
extent of migration into the scratched area was calculated after 48 h and revealed that both 
resveratrol and pterostilbene significantly inhibit cell migration, although pterostilbene had 
greater anti-migratory effect. (B) The graph represents data from triplicate sample experiments 
normalized to the control (mean % migrated cells ± S.E.M.; * p < 0.05). Scale bar: 0.05 µm. 
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2.3.3 Cell Cycle Arrest at S-Phase in HeLa Cells Treated with Low Concentrations of 
Resveratrol and Pterostilbene  
In order to compare the effect of sub-lethal doses of either resveratrol or pterostilbene on the cell 
cycle of HeLa cells, treatment was carried out with three different concentrations (5 µM, 10 µM, 
and 15 µM) of the two compounds for 18 h prior to flow cytometric analysis (Figure 3A). Flow 
cytometry analysis showed that the cells treated with either compound exhibited a significant 
decrease in the number of cells in the G2-M phase with respect to the control cells (p < 0.05) 
(Figures 3A, B, Table 3), indicating an S-phase cell cycle arrest. This effect corresponded with 
an increase in the number of cells arrested at the S-phase. Pterostilbene was significantly more 
potent than resveratrol in inhibiting cell cycle progression, showing effects at concentrations as 
low as 5 µM (p < 0.05) (Figures 3A, B, Table 3). At this concentration, pterostilbene had these 
percentages of cells in each phase: G1 = 53.4 ± 1.4, S = 34 ± 1.4, G2 =12.5 ± 0.2, while 
resveratrol had values of G1 = 64.8 ± 2.0, S = 16.3 ± 1.0, G2 = 18.3 ± 2.3. At a higher 
concentration (15 µM) both compounds significantly inhibited cells from entering into G2-M by 
arresting them in the S-phase, and difference between the extent of the arrest at this phase 
induced by the two compounds was significant (p < 0.05) (Figures 3A, B, Table 3).  
To confirm the cell cycle data, which indicated that both compounds are potent inhibitors of cells 
entering into G2-M, we investigated the status of the M-phase mitotic marker phospho-histone-
H3 by immunocytochemistry (Figures 3C, D). At concentrations of 10 µM, both compounds 
significantly suppressed the amount of cells positive for the mitotic marker phospho-histone-H3, 
when compared to the untreated cells control. Although resveratrol significantly suppressed the 
abundance of phospho-histone-H3 (mitotic cells) at 5 µM, when compared to the control cells, 
pterostilbene at this concentration was significantly more potent than resveratrol (Figure 3D). 
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Relative to the control, which was set at 100%, cells treated with 5 µM pterostilbene exhibited 
only 13.8% mitotic cells positive for the marker, which was significantly lower than the 
resveratrol-treated sample at this concentration, which had 60% mitotic cells (Figure 3D; p < 
0.05).  
 
Figure 3. S-phase arrest in HeLa cells treated with low concentrations of resveratrol and 
pterostilbene: (A) Flow-cytometric evaluation of HeLa cells untreated or treated with sub-lethal 
doses of resveratrol (Res) and pterostilbene (Pte) for 18 h. Treated cells exhibited S-phase arrest 
and a subsequent decrease in the number of cells in G2/M. Pterostilbene was a more potent 
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compound than resveratrol, showing a capacity to arrest cells at the S-phase at concentrations as 
low as 5 µM. (B) Graphical representation of the dose-dependent cell cycle effects induced by 
resveratrol and pterostilbene at three different concentrations (5 µM, 10 µM, and 15 µM). (B) 
The graph represents data from triplicate sample experiments normalized to the control (mean % 
cells in each phase ± S.E.M.) (C) Immunofluorescent images of HeLa cells probed for the M-
phase marker phospho-histone-H3 (serine10). HeLa cells were untreated or treated with 5 µM 
and 10 µM of resveratrol or pterostilbene. Immunofluorescent images display a decrease of 
histone-H3 in cells treated with both the compounds, the effects at 5 µM of pterostilbene is much 
greater than those of resveratrol (at 5 µM). (D) Graphical representation of the percent of mitotic 
cells calculated from immunofluorescent images reveal that resveratrol and to a greater extent 
pterostilbene are effective in decreasing the number of mitotic HeLa cells. The graph represents 
data from experiments obtained from triplicate samples normalized to the control (mean % 




Table 3. Table showing the percentage of cells in each phase of the cell cycle (% ± S.E.M.) 
after treatment with different concentrations of resveratrol (Res) and pterostilbene (Pte).  
 
G1 ± S.E.M. S± S.E.M. G2 ± S.E.M. 
Control 64.1±0.4 8.00±2.5 27.7±2.4  
Res 5µM 64.8±2.0 16.3±1.0 18.3±2.3 ^ 
Pte 5µM 53.4±1.4 + 34.0±1.4 * 12.5±0.2 ^ 
Res 10µM 58.5±0.2 26.5±0.2 * 14.4±1.0 ^ 
Pte 10µM 54.3±0.8 + 35.6±2.4 * 10.1±1.5 ^ 
Res 15µM 61.3±1.9 27.1±0.8 *,# 11.5±1.2 ^ 
Pte 15µM 52.3±2.0 + 40.1±3.4 *,# 7.7±0.5 ^ 
+ p < 0.05 relative to G1 control, * p < 0.05 relative to S control, ^ p < 0.05 relative to G2 control, 
# p < 0.05 relative to each other. 
2.3.4 Downregulation of Viral Oncoprotein E6 and Upregulation of Active-Caspase-3 in 
HeLa Cells Treated with Pterostilbene and Resveratrol  
In order to investigate how resveratrol and pterostilbene were affecting HeLa cell survival and 
cell cycle progression, we treated cells with either of the two compounds at sub-lethal (10 µM) 
and higher (50 µM) concentrations prior to analysis by immunostaining for E6, active caspase-3, 
and p53 (Figures 4A–C). At 10 µM, both resveratrol and pterostilbene failed to significantly 
affect levels of E6 and active caspase-3 levels relative to the control (Figures 4A, B). However, 
at 50 µM both compounds significantly suppressed E6 levels and elevated cleaved caspase-3 
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levels in treated cells relative to the untreated cells (Figures 3A–C). At this concentration (50 
µM), pterostilbene was significantly more potent than resveratrol at suppressing E6 levels 
(resveratrol = 0.77 ± 0.11: 23% decrease vs. pterostilbene = 0.57 ± 0.06: 43% decrease; p < 0.05) 
and simultaneously elevating active caspase-3. It should be noted that we were unable to detect 
any noticeable differences in the sub-cellular localization of E6 in treated cells (Figure 4A).  
 
Figure 4. Downregulation of viral oncoprotein E6 and upregulation of active-caspase-3 in 
HeLa cells treated with resveratrol or pterostilbene: (A) HeLa cells immunostained for E6 
levels (green) and counterstained with the nuclear dye 4’,6-diamidino-2-phenylindole (DAPI) 
(blue) after treatment with resveratrol (Res) and pterostilbene (Pte; 10 µM and 50 µM). Loss of 
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E6 proteins are visually evident in cells treated with 50 µM of either resveratrol or pterostilbene. 
(B) Cell image analysis of the E6 fluorescent data revealed a significant 43% decrease of E6 
protein levels in HeLa cells treated with pterostilbene at 50 µM and a 23% decrease of E6 levels 
in cells treated with resveratrol, both relative to the control. The graph represents data from 
experiments obtained from three independent experiments normalized to the control (mean % 
normalized to DAPI ± S.E.M.; * p < 0.05). (C) Immunofluorescent images probing for active-
caspase-3 (green) shows a corresponding enhanced activation of this mediator of apoptosis by 
both resveratrol and pterostilbene. 
2.3.5 Upregulation of Tumor Suppressor Protein p53 in HeLa Cells Treated with 
Pterostilbene and Resveratrol  
Concomitant with E6 suppression, 50 µM pterostilbene treatment for 22 h caused an 
upregulation of p53 in HeLa cells (Figures 5A, B). When compared to the control, pterostilbene 
treatment elicited a 2-fold increase in p53 levels (staining normalized to DAPI; Figure 5B; p < 
0.05). In comparison to the control, HeLa cells treated with 50 µM of resveratrol also caused an 
upregulation of p53 (1.75-fold increase; Figures 5A, B; p < 0.05) at 22 h.  
Total protein levels of p53 were also analyzed by Western blot in cells treated with either 
resveratrol (10 µM and 50 µM) or pterostilbene (10 µM and 50 µM) for 22 h (Figures 5C, D). 
Both compounds elevated p53 levels at 50 µM; however, significance was only noted in cells 
treated with pterostilbene at this concentration (Figures 5C, D). Although cells treated with 
pterostilbene at 10 µM tended to have elevated p53 protein levels relative to both the control 
cells and cells treated with 10 µM of resveratrol, these differences were not significant based on 




Figure 5. Upregulation of the tumor suppressor protein p53 in HeLa cells treated with 
resveratrol and pterostilbene: (A) Immunoflourescent images of p53 protein (green) untreated 
or after treatment with 50 µM of either resveratrol (Res) or pterostilbene (Pte) for 22 h. Levels of 
p53 are elevated in cells treated with either polyphenol. (B) Image analysis of p53 
immunofluorescence indicates that pterostilbene treatment at 50 µM elicited a significant 2-fold 
increase in p53, while resveratrol exposure at similar concentrations induced a significant 1.75 
increase in p53. The graph represents data from experiments obtained from three independent 
experiments normalized to the control (mean % normalized to DAPI ± S.E.M. * p < 0.05). (C) 
Western blot analysis also revealed that the elevation of p53 protein levels is evident in HeLa 
cells treated with 50 µM of resveratrol and pterostilbene; however, significant differences 
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relative to the control were only reached with HeLa cells treated pterostilbene at 50 µM. (D) The 
graph represents data from experiments obtained from three independent experiments normalized 




















In the current study, for the first time to our knowledge, we have compared the antitumor 
potency of resveratrol and pterostilbene on E6+ cervical cancer cells in vitro. We demonstrated 
that pterostilbene was significantly more potent than resveratrol in eliminating and in abrogating 
the clonogenicity of these cervical cancer cells (Figure 1). To assess and study the effects of the 
two compounds, we used a wide range of concentrations. Sub IC50 concentrations ranging from 
5–20 µM were used to understand the action of these polyphenols at a low concentration. The 
results show that at these concentrations the polyphenols can inhibit cell division and migration. 
To further understand the cytotoxic mechanisms, it was imperative for us to look at supra IC50 
concentrations. We used 50 µM to understand the mechanism of action. The clonogenic assay 
using this high concentration elucidates the long-term effect of these polyphenols on surviving 
cells even after the removal of treatment. While sub-IC50 values of both compounds inhibited the 
migration of E6+ cervical cancer cells, a higher sub-lethal concentration of resveratrol (20 µM) 
was needed to exert any significant inhibitory effect. Nonetheless, pterostilbene caused a more 
significant degree of inhibition to cell migration, attesting its superior antitumor potency (Figure 
2). It is a notion held by cancer researchers that sub-IC50 concentrations of chemotherapeutic 
drugs are ineffective in curtailing tumor malignancy. However, surprisingly, our data shows that 
even at a low sub-lethal concentration (5 µM), pterostilbene is more effective than resveratrol as 
an antiproliferative agent against cervical cancer cells by triggering cell cycle arrest at the S-
phase (Figure 3). In addition to being effective at sub-IC50 concentrations, the supra-IC50 
concentration of pterostilbene (50 µM) was also superior to resveratrol (at 50 µM) in suppressing 
E6 while upregulating p53 and active-caspase-3 expression, thus causing a greater degree of 
apoptosis-mediated cell elimination. This observed suppression of E6 and upregulation of p53 is 
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of paramount importance because HPV infection and cancer progression in cervical cells relies 
on the expression of the viral E6 oncoprotein which targets p53 for degradation by the 
ubiquitination [63,64]. Thus, untreated cervical cancer cells continue to proliferate in the absence 
of p53, unable to respond to cell stress and DNA damage. Our data indicates that resveratrol and 
pterostilbene may restore an adequate p53 response and ultimately act as anticancer plant 
compounds. 
A comparative study between resveratrol and pterostilbene on colon cancer cells had shown 
pterostilbene to be a more potent anticancer agent compared to resveratrol [32]. We hypothesized 
that in cervical cancer cells we would see a similar effect with higher induction of apoptosis with 
pterostilbene treatment. Our first approach to understand the comparative efficacy of resveratrol 
and pterostilbene in HeLa cells was a cytotoxicity analysis, in addition to ascertaining the 
inhibitory concentration (IC50) (Figure 1 and Video S1–S3). The results clearly indicated that 
pterostilbene could eliminate HeLa cells much faster and at a significantly lower concentration 
compared to resveratrol. We also further analyzed the cytotoxic potential of these polyphenols on 
a second cell line, E6-positive murine TC1 cells, and found a similar trend in IC50 results for 
resveratrol and pterostilbene, where pterostilbene is 2-fold more cytotoxic than resveratrol. Since 
cancer cells are known to have enhanced clonogenecity [59,65], our study aimed to see the 
survival capability of the cells treated with supra-IC50 concentrations of either resveratrol or 
pterostilbene. Clonogenic studies show the long term-term effects of these polyphenols on 
cervical cancer cells after treatment for 24 h and then allowing the surviving cells to grow in 
normal growth medium for 15 days. Both compounds at supra-IC50 concentrations showed a 
dramatic decrease in the clonogenic capacity of the surviving cells. These results suggest that 
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resveratrol and pterostilbene may suppress new tumor growth often seen in high-grade metastatic 
cervical cancer. 
The migration of cancer cells is a very important factor responsible for the metastasizing of 
cancers [66]. Inhibition of migration can play a major role in checking the progression of cancer 
metastasis. Our study found that sub-cytotoxic doses of both compounds exhibit anti-migratory 
roles. These findings are supported by previous studies, which have shown that resveratrol shows 
anti-migratory activity by suppressing phorbol 12-myristate 13-acetate (PMA)-induced migration 
in cervical cancer cells [67]. Studies in hepatocellular carcinoma indicate that pterostilbene 
suppresses migration by downregulating MMP-9 expression [68]. These mechanisms might 
possibly be responsible for inhibiting migration in HeLa cells and remain to be determined in 
later studies.  
Previous cell cycle arrest studies of resveratrol on HeLa cells showed that all the cells were 
arrested at the S-phase and none remained in the G2/M-phase [45,69]. Pterostilbene shows cell 
cycle arrest in several cancer studies [68]; however, to the best of our knowledge, no such study 
on cervical cancer has been carried out. Our current study showed that pterostilbene shows 
markedly better efficacy than resveratrol in arresting the cell cycle at the S-phase. To further 
analyze the effects of the two compounds on cell cycle arrest, we looked at phospho-histone H3 
as a marker for mitosis [70]. Our observations strengthen and confirm the results obtained from 
flow cytometric analysis indicating that although both compounds are able to arrest mitosis, 
pterostilbene has enhanced capacity to arrest cancer cell growth. 
Although we initially used sub-lethal concentrations of the two compounds on HeLa cells to 
decipher their antitumor mechanisms in the context of cell cycle arrest, it was imperative for us 
to delineate the possible mechanism of elimination of HeLa cells by these compounds at higher 
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concentrations. Pterostilbene is known to be effective on cervical cancer cells by Endoplasmic 
reticulum (ER)-mediated stress development as well as by targeting the Nrf-2 pathway [50]. In 
HPV+ cancer cells, the oncoprotein E6 degrades the tumor-suppressor protein p53 by targeting it 
for proteasomal ubiquitination, which has been shown to augment the tumorigenic characteristics 
of cancer cells [51,53]. In contrast, inhibition of E6 expression in the cancer cells would be 
expected to allow p53 protein to trigger apoptosis and cell cycle arrest. Our findings support this 
latter statement, with resveratrol and pterostilbene activating caspase-3 while simultaneously 
downregulating E6 and upregulating p53. Our findings are partly supported by previous studies 
indicating that resveratrol treatment on cervical cancer cell lines upregulates p53 [71]. Our 
findings are the first to show a direct upregulation of p53 in HeLa cells by another polyphenol, 
namely, pterostilbene. Importantly previous studies have shown that p53 and simultaneous 
caspase-3 activation might be the key for triggering apoptosis in HeLa cells [72]. Our 
experiments support this finding and ascertain that resveratrol and pterostilbene act as robust 
agents capable of regulating the p53-dependent apoptotic pathway. The p53 protein, which is 
usually very low in HeLa cells, was upregulated by resveratrol and pterostilbene, leading us to 
hypothesize that reactivation of p53 in treated HeLa cells is a possible mechanism of action of 
these compounds.  
Cervical cancer is a major concern in developing countries due to lack of affordable prophylaxis 
and treatment. As present modes of treatment like surgery, chemotherapy, or radiation involve 
high systemic toxicity, there is an urgent need to find affordable alternative therapies. Diet-based 
polyphenols like resveratrol and pterostilbene are therefore potential candidates for the effective 
therapy of cervical cancer with significantly low toxicity. We found pterostilbene to be a more 
potent anticancer agent than resveratrol in HeLa cells. This difference may be a function of 
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pterostilbene being capable of upregulating p53 and downregulating E6 significantly more than 
resveratrol. As pterostilbene is non-toxic to normal cells [37], it has the potential to be a robust, 
cost-effective anti-E6+ tumor drug. Others have found that that pterostilbene possess greater 
bioavailability and stability [73] than resveratrol in vivo (80% vs. 20%). Resveratrol has been 
shown to be non-toxic to several cells lines like glial cells and neurons, even after a treatment 
dose of 100 µM for 48 h [74]. Other studies on normal fibroblasts also state the non-toxicity of 
resveratrol at our observed potent anticancer concentrations [75]. Additionally, pterostilbene 
shows no toxicity at these concentrations in normal skin fibroblasts and myoblasts [76]. 
According to clinical studies, the safe dosage for resveratrol and pterostilbene is 5 g/day [29]and 
250 mg/day [37], respectively. Our findings support the further evaluation of pterostilbene as a 
possible therapy against cervical cancer. 
Here, we show that pterostilbene potently suppresses HPV E6 expression (Figure 4) and 
efficiently eliminates HPV+ cells in culture by p53-mediated apoptosis (Figures 1 and 5) while 
suppressing cell proliferation (Figure 3) and migration (Figure 2). We find that pterostilbene is a 
more promising agent against cervical cancer when compared to resveratrol. Based on such 
properties, the use of pterostilbene presents a relatively economical but highly hopeful 
therapeutic approach to treat HPV infections and cervical cancers. Our future studies will include 
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Human papilloma virus (HPV) induced-cervical cancer is one of the most frequent cancers in 
women residing in underdeveloped countries. Natural compounds like polyphenols continue to 
be of scientific interest as non-toxic effective alternative treatments. Our previous work showed 
the efficacy of two polyphenols, resveratrol and pterostilbene on human HeLa cells. Here we 
explored the in vitro anti-cancer activity and in vivo anti-tumor potential of these two structurally 
similar compounds on HPV oncogene E6 and E7 positive murine TC1 cells. In vitro analysis 
confirmed the cytotoxic potential of both resveratrol and pterostilbene compounds with each 
having a low IC50 value and each showing the ability to downregulate viral oncogene E6. Further 
our in vivo studies on TC1 tumors developing in mice indicated that treatment with either 
resveratrol or pterostilbene can significantly inhibit tumor development. with both compounds 
capable of downregulating E6 and VEGF tumor protein levels. Interestingly, the decrease in 
tumor size in pterostilbene was associated with tumor cell apoptosis, as indicated by an 
upregulation of activated caspase-3 whereas in resveratrol-treated mice it was accompanied by 
arrest of cell cycle, as indicated by a downregulation of PCNA Thus, resveratrol and 
pterostilbene can serve as potential antineoplastic agents for HPV E6+ tumors and hyperplasia, 








3.2 Materials and Methods  
3.2.1 Cell Culture. TC-1 mouse cells were procured from the lab of Dr. T.C. Wu at Johns 
Hopkins University. TC-1 cells were derived from primary lung epithelial cells of C57BL/6 mice 
after co-transformation with HPV16-E6, HPV16-E7 and c-Ha-Ras oncogenes [77]. The cells 
were maintained in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) 
(HyClone, GE Healthcare Life Sciences, Manassas, VA, USA), supplemented with 10% fetal 
calf serum (HyClone, GE Healthcare Life Sciences) with 0.1% Penicillin-Streptomycin Solution 
(HyClone). Cells were cultured in a humidified incubator at 37 °C incubator and 5% CO2.  
3.2.2 Determination of IC50 Using WST-1 Assay. Four thousand TC-1 cells were plated on 96-
well plates and cultured for 24 hrs. Resveratrol (Acros, #430075000 ; > 99% purity tested by 
HPLC) or pterostilbene (TCI, #P1924 : > 98% purity tested by HPLC) were serially diluted from 
5–100 µM in DMEM/F-12 supplemented with 1 × insulin-transferrin-selenium (ITS; Invitrogen). 
Treatment was carried out with the dilutions (in triplicate) for 72 hrs after which time a WST-1 
(Water Soluble Tetrazolium salt-1; Clontech, Mountain View, CA, USA) cell viability assay was 
performed. The medium was aspirated after treatment and rinsed three times with 1 × Phosphate 
Buffered Saline (PBS). After rinsing, 80 µL of a 10% WST-1 fresh solution was prepared in 
DMEM and subsequently added to each well. The plate was then incubated for 1 hr at 37°C to 
get a color reaction. The absorbance was recorded at 440 nm using a 96-well spectrophotometer. 




3.2.3 Immunocytochemistry. TC-1 cells were cultured on 8-well chamber slides for 48 hrs prior 
to immunocytochemistry. The cells were then untreated (control) or treated with resveratrol (30 
µM) or pterostilbene (30 µM) for 48 hrs prior to immunocytochemical detection of E6. The 
dilutions of resveratrol and pterostilbene were done in serum-free DMEM/F-12 containing 1% 
supplement (ITS; insulin, transferrin, selenium; Gibco BRL, Grand Island, NY, USA). After the 
completion of the treatment period the cells were fixed in 4% paraformaldehyde. Further 
processing of the fixed cells and probing with E6 antibody (sc-460; Santa Cruz Biotechnology) 
was carried out as described previously [78]. 
3.2.4 TC-1 mouse model generation and treatment. 50,000 TC-1 cells harvested from actively 
growing cultures were injected subcutaneously in the nape of the neck of female C57BL/6 mice, 
which were approximately 2-3 months old. This tumor model has been standardized and used in 
previous studies [21,79]. Once palpable tumors were formed (in approximately 15-20 days) 
treatment cycles was initiated. Treatment involved the mice being randomly divided into three 
groups, control, resveratrol and pterostilbene - with each group containing 4 mice. Tumors were 
marked into four quadrants and 10 µl of the 1 mM resveratrol or 1 mM pterostilbene was 
injected into each quadrant intralesionally for 5 consecutive days. The control group of mice 
were subjected to 1 x PBS injections also for 5 consecutive days. After the completion of the 
treatment cycle the mice were sacrificed and the tumors were excised. Tumor volumes for the 
excised tumors were measured using a caliper and volumes were calculated as previously 
mentioned [21]. Tumors were then fixed and processed for immunohistochemistry. All mouse 
experiments were performed according to NIH guidelines for animal use and approved by the 
Institutional Animal Care Committee (IACUC) of the College of Staten Island (CUNY) 
(approval # 11−008). 
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3.2.5 Immunohistochemistry. Tumor sections that were taken from the approximate center of 
the tumor were randomly selected from each group for immunohistochemical analysis. The 
sections were first subjected to antigen-retrieval using formamide: 2 × SSC at 55°C for 2 hr 
followed by two PBS washes. The sections were then blocked with 3% goat serum or 10% rabbit 
serum for 2 hrs and then treated overnight with primary antibodies: anti-E6 antibody (sc-460; 
Santa Cruz Biotechnology) or VEGF (P-20; Santa Cruz Biotechnology) or PCNA (#2586 Cell 
Signaling Technology) or Cleaved Caspase-3 (Asp 175) (#9661; Cell Signaling Technology). 
The antibodies were diluted in 2% goat serum or 2% rabbit serum and 0.1% Triton X in PBS. 
The sections were washed with PBS after the primary treatment and then probed with the 
secondary antibody. For E6 primary antibody the secondary antibody used was Alexa Fluor 488 
goat anti-mouse (Invitrogen) and for VEGF primary the secondary antibody used was Alexa 
Fluor 488 rabbit anti-goat (Invitrogen). Sections were also stained only with the secondary 
antibodies as a negative control for the experimental setup. After overnight incubation with 
secondary antibody at 4 °C the sections were washed and stained with nuclear stain DAPI 
(10 µg/ml) for 15 min at room temperature. The sections were then mounted on a slide with Gold 
anti-fade mounting fluid. Confocal Images of the immunostained sections were taken using a 
Leica SP2 microscope from multiple randomly chosen fields of multiple sections. 
3.2.6 Image quantification and data analysis. All images taken were quantified using ImageJ 
software. The empirical data obtained from all experiments were analyzed using GraphPad Prism 
7 software. 
3.2.7 Statistical analysis. Statistical analyses were performed using GraphPad Prism® 7 
(GraphPad Software, Inc., La Jolla, CA, USA). The mean and standard error mean was obtained 
for the groups. One-way ANOVA with Tukey test was used to compare the data sets and 
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3.3.1 Resveratrol and Pterostilbene are cytotoxic to TC1 cells. Based on the findings of our 
previous studies on HeLa cells showing the cytotoxic potential of resveratrol and pterostilbene 
[78], we wanted to determine their anticancer efficacy on HPV-E6-positive mouse TC1 cells. 
Brightfield images were taken after 48 hrs of treatment with different concentrations of 
resveratrol or pterostilbene to see their cytotoxic potential relative to untreated control cells 
(Figure 6A). A qualitative analysis of the images indicates that compared to control untreated 
cells, both resveratrol and pterostilbene show significant cytotoxicity, with pterostilbene showing 
more cell death and cytoplasmic blebbing than resveratrol after 48hrs. These comparative effects 
are visible even at low concentrations of 10 µM and apoptotic cell numbers increased in a dose 
dependent manner for both treatment groups. Analytically we ascertained the IC50 concentrations 
of these two polyphenols by performing a WST-1 assay for cell viability (Figure 6B). The results 
showed the IC50 of resveratrol to be 34.46 µM (Figure 6Bi) while that of pterostilbene was 
greater than 2-fold less at 15.61 µM (Figure 6Bii). These IC50 values were significantly different 
from each other (p < 0.0001) and confirm the superior cytotoxicity of pterostilbene over 




Figure 6. Resveratrol and pterostilbene are cytotoxic to TC1 cells. (A) Brightfield analysis of 
TC1 cells untreated (Control) or treated with 10 µM ,20 µM and 30 µM of resveratrol (Res) or 
pterostilbene (Pte). (B) IC50 values generated using a water soluble tetrazolium salt-1 (WST-1) 
assay after 72 hrs of exposure to resveratrol or pterostilbene shows that pterostilbene is more 
cytotoxic than resveratrol (IC50 = 15.61 µM vs. IC50 = 34.46 µM; p <0.0001, n =3). (Biii) Bar 
graph represents comparative data showing the difference in viable cells treated with resveratrol 




3.3.2 E6 oncoprotein gets downregulated by resveratrol and pterostilbene in vitro. To 
investigate whether the expression of HPV viral oncoprotein E6 was attenuated by either 
polyphenol treatments, we used immunocytochemical techniques to probe for protein levels in 
TC1 cells. Using the results from the brightfield images and the IC50 values we selected a supra 
IC50 concentration at 48 hrs for treatments (30 µM). Immunocytochemical analysis indicated that 
cells treated for 48 hrs with pterostilbene but not resveratrol had significantly lower E6 levels 
when compared to control (Figure 7A, B; p < 0.0001). Although E6 expression levels in 
resveratrol treated cells were downregulated by 12% compared to control this down regulation 
was not statistically significant (Figure 7B; p=0.1838). The downregulation of E6 levels by 
pterostilbene was also significantly different than resveratrol (p < 0.0002).  Therefore, our results 
show that in vitro pterostilbene is more potent in downregulating the essential oncoprotein E6 in 




Figure 7. Viral oncoprotein E6 gets downregulated in TC1 cells treated with resveratrol or 
pterostilbene. (A) TC1 cells immunostained and probed for E6 oncoprotein (green) and 
counterstained with nuclear stain DAPI (blue). Cells treated for 48 hrs with resveratrol (30 µM) 
or pterostilbene (30µM) shows pterostilbene has a more significant downregulation of E6 protein 
expression as compared to resveratrol and control. B) Bar graph indicates the percent decrease in 
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E6 expression in treated TC1 cells as compared to control untreated TC1 cells. The graphs 
represent data from three independent experiments (mean ± S.E.M.; * p < 0.05; B). 
 
3.3.3 Reduction of tumor size in mouse model by resveratrol and pterostilbene. To find out 
the potency of these two polyphenols in vivo we generated mouse tumors by implanting TC1 
cells subcutaneously in syngeneic C57Bl/6 female mice. After palpable tumors were formed, we 
treated the mice intralesionally with resveratrol and pterostilbene for 5 consecutive days. After 
completion of the treatment cycle the tumors were excised, and the volume of the tumors were 
measured using a caliper and volumes were calculated as mentioned previously [21] (Figure 
8A).The tumor size was drastically lower than the untreated tumors for both the treatment 
groups. The radical decrease of tumor load clearly shows the high anticancer and tumor 
inhibitory potential of resveratrol and pterostilbene (Figure 8B). Tumor volumes were measured 
and graphed showing that the tumor size decreased by 83.6% in resveratrol treated groups and 
72% in pterostilbene treated groups (Figure 8C). The reduction of size for both treatment groups 




Figure 8. Inhibition of tumor growth in E6+ tumor bearing mouse. A) Schematic 
representation of mouse TC1 tumor in vivo tumor generation and subsequent treatment cycle. 
TC1 cells were injected subcutaneously in 12 mice followed by daily palpations. After 15 to 20 
days, when the tumors became apparent mice were divided into three groups of 4 and treated 
intralesionally with either PBS (control), resveratrol or pterostilbene for 5 consecutive days. 
After 5 days the mice were sacrificed, and the tumor excised. B) Tumors excised from the 3 
groups, displayed for imaging and measured for size. In both treatment group tumors show 
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marked decrease in tumor size compared to control. C) Bar graph shows percent reduction in 
tumor size in mice treated with resveratrol or pterostilbene in comparison to control tumor. 
Tumor size reduction is significant in the treated groups. The graphs represent data from 4 mice 
from each group (mean ± S.E.M.; * p < 0.05; C). 
 
3.3.4 Reduction of E6 oncoprotein level in vivo by resveratrol and pterostilbene. To 
determine if E6 is downregulated in the resveratrol and pterostilbene treated tumors we used 
immunohistochemistry. E6 protein levels can be seen to be very high in control untreated tumor 
sections (Figure 9A). However, the treated groups show much lower expression of E6 indicating 
that both the polyphenols can target E6 for downregulation. In control tumors almost all the cells 
are E6 positive with high level of expression. In resveratrol and pterostilbene treatment not only 
are the number of E6 positive cells reduced but also the level of protein expression in these cells 
is lower. The fluorescence intensities of the tumor sections were compared and graphed (Figure 
9B). Resveratrol has an intensity of 20.6±5.1 (79% decrease vs. control) and pterostilbene has a 
total intensity of 10.5±2.2 (89% decrease vs. control). These finding indicate that both 
polyphenols can significantly downregulate the expression of E6 in murine tumors compared to 




Figure 9. E6 expression is reduced in mouse tumors. A) Tumor sections immunostained with 
E6 antibody shows decreased E6 protein (green) in mice treated with resveratrol or pterostilbene 
when compared to control untreated tumors.  Sections were counterstained with DAPI (blue). 
Scale bar: 47.62 µm. B) Graph indicates the significant reduction of E6 expression levels in 
resveratrol or pterostilbene treated tumors in comparison to control tumors sections (mean ± 




3.3.5 Downregulation of PCNA protein in vivo by resveratrol and upregulation of cleaved 
caspase 3 by pterostilbene. To understand the underlying mechanism(s) of tumor inhibition by 
these two polyphenols we analyzed by immunohistochemistry the apoptotic marker, activated 
caspase-3 (Figure 10 A, B), and the proliferation marker, PCNA (Figure 11 A, B). These results 
indicated that tumors treated with pterostilbene have a significant amount of activated caspase-3 
protein compared to resveratrol and control tumors (Figure 10A). The percentage of apoptotic 
cells represented graphically in Figure 10B indicates that in vivo resveratrol treatment does not 
appear to activate the process of caspase-3-mediated apoptosis whereas pterostilbene treatment 
significantly increased this pathway (16.34% vs. 2.72%; p<0.0001). The difference in activation 
of caspase-3 by pterostilbene is also significantly greater than tumors treated with resveratrol (p 
< 0.0001). In contrast resveratrol treated tumors showed a significantly lower expression of 
PCNA compared to untreated and pterostilbene treated tumors (Figure 11A). The percentage of 
cells expressing PCNA reduced by 75.5% in resveratrol treated tumors compared to control 
(25.26±10.5 vs 100±5.6; p < 0.0004). Moreover, the downregulation of PCNA positive cells by 
resveratrol is significantly different than tumors treated with pterostilbene (p < 0.0006). Taken 
together these results show that resveratrol targets a downregulation of proliferation (Figure 11A, 
B) whereas pterostilbene activates apoptosis in TC1 tumors (Figure 10A, B), with both 





Figure 10. Upregulation of activated caspase 3 in mouse tumors. A) Tumor sections 
immunostained with cleaved caspase 3 antibody shows elevated protein levels (green) in mice 
treated with pterostilbene when compared to control untreated tumors. Resveratrol treated tumors 
did not show any significant change in caspase 3 expression.   Sections were counterstained with 
DAPI (blue). Scale bar: 47.62 µm. B) Graph indicates the significant increase of Cleaved caspase 
3 expression levels in pterostilbene treated tumors in comparison to control tumors sections 





Figure 11. Downregulation of PCNA expression in mouse tumors. A) Tumor sections 
immunostained with PCNA protein (green) and counterstained with nuclear stain DAPI (blue). 
Resveratrol treated tumors display a significant decrease in PCNA expression compared to 
control sections. Pterostilbene treated tumors show similar PCNA levels as control.  Scale bar: 
47.62 µm. B) Quantitative analysis of PCNA expression shows a significant change in 
resveratrol treated tumor sections (mean ± S.E.M.; * p < 0.0004; B). The two treatment groups 
show significant differences in PCNA expression (p< 0.0006). 
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3.3.6 Downregulation of VEGF protein in vivo by resveratrol and pterostilbene. E6 is 
known to upregulate VEGF expression in HPV positive tumor cells [80] therefore, we analyzed 
VEGF expression as a biomarker for E6 loss of function. Immunohistochemical analyses of 
tumor tissue showed that VEGF expression is lowered by the treatment of either resveratrol or 
pterostilbene (Figure 12A). Control tumor sections show a high expression of VEGF whereas 
treatment with either resveratrol or pterostilbene lowered the protein levels. The reduction is seen 
ubiquitously throughout the tumor sections in both the treated groups. The graph ascertains the 
level of downregulation with resveratrol showing a reduction to 60.5% (60.57±3.13) and 
pterostilbene to 66.8% (66.88±2.8) compared to control (100%) (Figure 12B). Both treatments 




Figure 12. Downregulation of VEGF expression in mouse tumors. A) Tumor sections 
immunostained with VEGF protein (green) and counterstained with nuclear stain DAPI (blue). 
Both resveratrol and pterostilbene treated tumors display a significant decrease in VEGF 
expression compared to control sections. Scale bar: 47.62 µm. B) Quantitative analysis of VEGF 





In the current study we have elucidated for the first time the efficacy of stilbene compounds, 
resveratrol and pterostilbene using an in vivo murine E6 positive tumor model. We first 
demonstrated that in vitro pterostilbene shows a higher efficacy in eliminating TC1 E6-positive 
cells, when compared to resveratrol (Figure 6). It is important to note that both compounds show 
significant cytotoxicity when compared to untreated cells. Analytically, we determined that the 
IC50 of pterostilbene was approximately 2-fold less when compared to resveratrol (Figure 6). 
Further in vitro analysis revealed that pterostilbene targeted significant downregulation of the 
HPV oncoprotein E6 (Figure 7), which drives these cells to form tumors in vivo. In comparison, 
cells treated with resveratrol exhibited less E6 compared to untreated controls, but the results 
were not statistically significant (Figure 7). Both the compounds were unable to elicit significant 
changes in E7 levels in TC1 cells (Figure 13). The in vitro results show that these polyphenols 
are cytotoxic to TC1 cells and both show promise in downregulating the oncoprotein E6 with 
pterostilbene showing superior antitumor potential (Figure 6,7).  
To evaluate the efficacy of these polyphenols in vivo we established TC1 tumors in C57BL/6 
mice and subjected them to intralesional treatment with 5 daily injections of 10 ul of resveratrol 
(1mM) or pterostilbene (1mM). At the end of the treatment cycle, tumors treated with either 
resveratrol or pterostilbene were significantly smaller than those treated with 1 x PBS alone 
(Figure 8). Resveratrol was able to reduce tumor size an average of 83 % while pterostilbene 
reduced tumor size an average of 72 %, when compared to control. The difference in tumor 
reduction between resveratrol and pterostilbene was not significant, which was unexpected given 
the potency of pterostilbene to more efficiently reduce E6 in vitro. When we assessed the E6 
protein levels by using immunohistochemistry on tumor tissue we found resveratrol and 
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pterostilbene both significantly inhibit E6 expression when compared to PBS (control) treated 
tumors, although resveratrol downregulated E6 to a lesser extent (Figure 9). Upon further 
examination we were able to demonstrate that pterostilbene causes significant apoptosis in the 
tumors whereas resveratrol plays a major role in arresting the growth of these tumors. Therefore, 
this study shows for the first time, to the best of our knowledge that resveratrol and pterostilbene 
can exhibit antitumor activity and reduce tumor load by two distinct mechanisms; resveratrol 
through cell cycle arrest (down regulation of PCNA) and pterostilbene through apoptosis 
(upregulation of caspase-3; Figure 10,11). Of the multiple possible downstream targets of E6, 
VEGF overexpression is of supreme importance in cervical cancer biology [80]. Delving deeper 
into the possible targets of these polyphenols we found that angiogenic protein VEGF is 
significantly reduced by both these natural compounds (Figure 12). Thus, our findings show the 
potency of resveratrol and pterostilbene on TC1 tumors by downregulating the oncoprotein E6, 
which drives TC1 tumor growth. The robust capability of these natural plant compounds to arrest 
and eliminate E6 positive tumor cells is promising for those researchers looking for alternative 
therapies to cervical cancer or for a better understanding of E6 oncogene activity.  
We first confirmed the cytotoxic potential of resveratrol and pterostilbene on TC1 cells in vitro. 
Our results showed that pterostilbene is 2-fold more potent than resveratrol in eliminating TC1 
cells (Figure6). This corroborated our previous findings on HeLa cells where we had seen a 
similar pattern of IC50 with pterostilbene showing superior efficacy than resveratrol [78]. HPV 
E6 oncoprotein is known to play an essential role in cervical carcinogenesis. Both E6 and E7 
protein expression is required for continuous cell proliferation and metastasis. Studies have 
confirmed that eliminating E6 oncoprotein pushes the cells towards cell growth arrest and 
apoptosis [53,54]. Our previous study on HeLa cells showed that although both resveratrol and 
55 
 
pterostilbene downregulate E6 expression, pterostilbene has higher inhibitory efficacy compared 
to resveratrol [78]. In the current study we see a similar trend in E6 level suppression, with 
pterostilbene treatment showing greater suppression of E6 protein levels than resveratrol 
treatment (Figure 7). This increased efficacy of pterostilbene may be attributed to its structural 
stability. The methoxy group in pterostilbene makes it more lipophilic and more bioavailable 
than resveratrol which has a single hydroxyl group [38,73]. Pharmacokinetic studies have also 
established the superior bioavailability of pterostilbene over resveratrol [73,81]. 
Previous studies by our team on the human cervical cancer cell line HeLa also showed the 
cytotoxic potential and anticancer properties of these two polyphenols in vitro [78]. Here our aim 
was to further validate these compounds as promising cervical cancer therapies and to more 
importantly evaluate their anticancer potential using in vivo model of cervical cancer. To achieve 
this goal, we used TC1 cells which are E6, E7 and c-Ha-Ras positive transformed mouse 
epithelial cells. Due to a lack of cervical cancer mouse models, TC1 cells have been widely used 
for creating E6-positive mouse tumors to test vaccines and other therapies [21,77,82]. Several 
studies have utilized this model to understand the role the immune system and microenvironment 
in HPV cancers and also study immunotherapeutic strategies [79,83,84]. Combinatorial studies 
using natural compounds including resveratrol has been successfully tested on TC1 tumor 
models [21,79]. However, there has been no study that has investigated the potential of 




Figure 13. E7 expression in TC1 cells. A) TC1 immunostained with E7 protein (green) and 
counterstained with nuclear stain DAPI (blue). Both resveratrol and pterostilbene treated cells 
were unable to cause significant change in protein expression. 
 
Several in vivo studies show that resveratrol has anticancer properties against breast cancer, 
colorectal cancer and liver cancer in rat and mouse tumor models [28]. In humans, resveratrol is 
well tolerated with low toxicity and multiple clinical trials have proven the beneficial effects of 
this polyphenol on colorectal cancer and breast cancer to name a few [40]. Pterostilbene has 
gained a lot of attention in recent years as a more potent bioavailable analog of resveratrol. 
Clinical trials also indicate the low toxicity of pterostilbene up to 250 mg/day dosage [37]. 
Pterostilbene has shown potential in abrogating several cancers like breast and colon cancer in 
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animal models [36]. Although preclinical studies show the potency of pterostilbene on several 
types of cancers , there is a lack of large scale clinical studies [38]. The in vivo efficacy of these 
two polyphenols on cervical cancer has also not been substantially explored. Our studies bring to 
light their strong potential to reduce tumor growth in a mouse cervical cancer model. The results 
show support toward clinical trials investigating resveratrol and pterostilbene in late stage 
cervical cancer, when local resection of tumor is not effective or as a possible preventative 
treatment to those individuals with chronic HPV cervical infection in the absence of tumor.  
Suppression of apoptosis and uncontrolled proliferation are major steps essential for progression 
and metastasis of cancer [54]. Resveratrol and pterostilbene are known to have proapoptotic, 
chemo preventative and anticancer properties [34]. Keeping in mind the extensive reduction of 
tumor growth seen in vivo we wanted to explore if resveratrol and pterostilbene trigger the 
apoptotic pathway. Several studies have shown that both these polyphenols can induce apoptosis 
in several cancer cell lines including cervical cancer [32,44,78,85]. Our result showed that 
pterostilbene but not resveratrol is able to induce considerable apoptotic cell death in TC1 tumor 
cells in vivo. The upregulation of pro-apoptotic activated caspase-3 by pterostilbene was 
significantly higher than untreated tumors whereas, resveratrol showed barely any change 
(Figure 10). The difference in caspase-3 activation between the two treatments was statistically 
significant and it was surprising to us given resveratrol’s potency to induce cell death in our in 
vitro studies. We then further analyzed the growth inhibitory effects of these two polyphenols in 
tumor tissue by performing immunohistochemistry for PCNA. PCNA is known to be highly up 
regulated in HPV positive cancers [86] and is known to play a major role in cancer neoplasia 
[87]. Our results showed that resveratrol, but not pterostilbene, can drastically downregulate 
PCNA expression in TC1 tumors. The untreated and pterostilbene treated tumors had similar 
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PCNA expression patterns (Figure 11). Our findings elucidate that resveratrol and pterostilbene 
reduce tumor size by possibly two different mechanisms, resveratrol by downregulating growth 
and pterostilbene by upregulating death of tumor cells. It is known that pterostilbene is more 
bioavailable than resveratrol in vivo [73,88]. In our studies on HeLa cells we had seen that 
resveratrol can cause cell cycle arrest at a sub IC50 concentration [78]. We think that possibly 
pterostilbene being more bioavailable is absorbed more in the tumor resulting in a higher internal 
concentration compared to resveratrol which being less bioavailable results in a lower intra-
tumoral concentration. Based on our previous study and current results we hypothesize that 
resveratrol with a lower tumor concentration induces cell cycle arrest whereas pterostilbene 
remains at a high concentration within the cell and thus triggering apoptosis.  
HPV E6 is an oncoprotein which has several important targets that can affect cellular pathways 
leading to oncogenesis [52]. Studies have shown that HPV E6 is associated with activating the 
promoter for VEGF gene in cervical cancers [80]. VEGF is known to induce angiogenesis, tumor 
cell proliferation and plays a vital role in cervical neoplastic progression [89]. Current therapies 
for recurrent cervical neoplasia include the usage of bevacizumab (Avastin) which is an anti-
VEGF antibody [48]. Unfortunately treatment with Avastin is associated with several serious 
side effects including hemorrhaging [48]. Previous studies have shown that resveratrol can 
inhibit angiogenesis by targeting HIF-1α and VEGF in cervical cancers cells [48]. Pterostilbene 
has also shown anti-angiogenic properties in skin and lung cancers [36]. However there have 
been no studies evaluating pterostilbene’s efficacy in cervical cancer. In the current study we 
found that both resveratrol and pterostilbene can downregulate VEGF expression and therefore 
should be further evaluated as alternative or complement to current anti-angiogenic cervical 
cancer therapies.  Both treatment groups can downregulate VEGF expression equally (Figure 
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12). As VEGF is an important target for therapy our findings establish the therapeutic potential 
of resveratrol and pterostilbene in HPV positive cancers.  
Cervical cancer remains prevalent in many countries where anti-HPV vaccines and preventative 
preneoplastic assessments are not routinely provided. Here we provide strong evidence that the 
natural compounds pterostilbene and resveratrol are effective in drastically shrinking a cervical 
cancer tumor model in vivo when injected directly into the tumor. Further studies, analyzing our 
tumor model treated with systemic injections of these compounds is the next appropriate step. 
Given these compounds are well tolerated in humans, they may provide clinicians with a viable 
therapy in the treatment of cervical cancer, especially when current therapies are not available 
















































4.1 Concluding Remarks 
This study elucidates the anti-cancer properties of two structurally similar natural compounds, 
resveratrol and pterostilbene in vitro and in vivo. Our studies on HeLa cells showed the superior 
anticancer properties of pterostilbene over resveratrol. Both the polyphenols were able to cause 
apoptosis at higher concentration and arrest proliferation at lower concentrations. We were able 
to link the cellular toxicity of these compounds to be a function of E6 downregulation. The 
extent of E6 downregulation corresponds to a concurrent upregulation of p53 expression which 
leads to apoptotic cell death. The polyphenols arrested cell cycle, stopped cell migration and 
reduced the clonogenic potential of the cancer cells. In all the studies on HeLa cells it was clearly 
seen that pterostilbene had a higher potency than resveratrol to annihilate and arrest metastasis 
and invasion.  
To further investigate if these effects can be translated in vivo, we used TC1 implanted mice. 
After the completion of the treatment cycle a drastic reduction in tumor size was seen in both the 
treatment groups. Unlike the in vitro results which showed pterostilbene to be more potent, the in 
vivo tumor studies showed there is no difference in their tumor inhibiting potential. When we 
delved in deeper to understand the targets, we found E6 to be downregulated along with 
angiogenic marker VEGF. Surprisingly, the two compounds inhibited the tumor growth by 
possibly two different pathways. Pterostilbene treatment caused apoptosis in the tumors whereas 
resveratrol treatment inhibited cell proliferation. This shows the tumoricidal potential of 
pterostilbene versus the tumoristatic potential of resveratrol. The potential of resveratrol to 
inhibit tumor progression provides proof of its efficacy and negates the possibility of it being a 
pan assay interfering compound. 
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The ability of resveratrol and pterostilbene to be cytotoxic to cervical cancer cells and tumors 
may be via a p53 dependent or independent pathway. E6 being the major target of both these 
compounds several effector pathways may be disrupted. Our study on HeLa cells indicated that 
both these polyphenols may be causing apoptosis by a p53 mediated pathway. A stabilization of 
p53 or an upregulation of p53 may have been induced by downregulation of oncoprotein E6. 
Recent study using resveratrol on HeLa cells have shown similar results with elevated p53 
leading to apotosis [90]. E6 is able to effect several proteins besides p53 that can lead to 
apoptosis. In our study we have looked at the effect of resveratrol and pterostilbene on some of 
the major hallmarks of cancer (Illustration 3). As resveratrol and pterostilbene can downregulate 
E6 in both HPV 16 and HPV18 strains we presume that there are multiple pathways that are 
being affected which leads to tumor growth reduction and inhibition. Both the polyphenols are 
pleiotropic and are effective against different types of tumors concurrently being non toxic to 
normal cells. Further studies are required to fully understand the underlying meachanism of 




Illustration 3. Hallmarks of cancer targeted by E6. [91] 
The robust antitumor action of resveratrol and pterostilbene in vivo gives a valuable new 
information in the field of natural compounds in cervical cancer and can be used as a potential 








4.2 Future Directions: 
This work raises some important questions. 
Q1. What would be the outcome of a long-term treatment? 
 Our in vivo study was only limited to 5 consecutive days. Question remains if the long-term 
treatment can eliminate the tumors completely and result in disease free survival.  
Q2. Will removing the treatment result in tumors coming back and will the two compounds 
show a difference? 
Our study showed that resveratrol stops tumor proliferation whereas pterostilbene causes tumor 
cell death. It is possible that on removal of the treatment the tumors treated with resveratrol can 
bounce back and start dividing. Is the pterostilbene treatment more potent as it is irreversible cell 
death? 
Q3. What are the other targets of these compounds? 
There are several other pathways that regulate the process of metastasis. Further analysis of 
differential and altered protein expression needs to be done to understand the mechanism of 
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